Pulse Biosciences, Inc. (PLSE) Stock Price & Analysis
Pulse Biosciences, Inc. (PLSE) closed at USD 45.59 on Thursday, October 15, 2026, down 1.58% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 45.59; the Oct 15, 2026 session ranged USD 43.96–46.67 on volume of 425,629 shares. Market capitalization is —, with a 52-week range of USD 12.56–58.9 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:19 UTC.
Also available as compact Markdown for AI agents: nexqual.com/PLSE.md
Key facts (PLSE)
- Analysts: Buy (mean 1.83 on a 1–5 scale) (6 analysts), mean target USD 62.33 (range 55–73).
- Total return with dividends: 1Y +159.5% vs S&P 500 +18.1%; 5Y +110.6% vs S&P 500 +85.1%.
- Next earnings: 2026-11-05, EPS estimate USD -0.29, revenue estimate $522K.
Analysts (PLSE)
Consensus Buy (mean 1.83 on a 1–5 scale), 6 analysts; mean target USD 62.33 (low 55, high 73).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-13 | Oppenheimer | Target raised | Outperform | $35 → $60 |
| 2026-10-06 | Canaccord Genuity | Target raised | Buy | $43 → $58 |
| 2026-09-23 | BTIG | Initiated | Buy | $70 |
| 2026-09-09 | Freedom Capital Markets | Initiated | Buy | $73 |
| 2026-08-17 | Needham | Initiated | Buy | $58 |
| 2026-08-10 | Canaccord Genuity | Target raised | Buy | $32 → $43 |
Total return (dividends reinvested) (PLSE)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | +159.5% | +110.6% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +160.3% | +16.0% |
| Volatility (annualized) | 82.1% | 94.8% |
| Max drawdown | -30.5% (Oct 2025→Nov 2025) | -94.4% (Nov 2021→Aug 2022) |
Key Statistics (as of October 16, 2026 at 05:19 UTC)
| Price | USD 45.59 |
|---|---|
| Change | ▼ 1.58% (down) |
| Previous Close | USD 45.59 |
| Open | USD 45.59 |
| Day Range | USD 43.96 – 46.67 |
| 52-Week Range | USD 12.56 – 58.9 |
| Volume | 425,629 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (PLSE)
Nexqual's technical model rates PLSE "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:19 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 41.33 (neutral) |
| vs SMA50 | Below (USD 49.48) |
| MACD | -0.37 (negative) |
Analyst Ratings (PLSE)
Wall Street analysts rate PLSE "Buy" based on 6 analysts, with a mean price target of USD 62.33 (range USD 55–73), per Nexqual as of October 16, 2026 at 05:19 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 62.33 |
| High Target | USD 73 |
| Low Target | USD 55 |
| Buy / Hold / Sell | 6 / 0 / 0 |
Earnings (PLSE)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.29 |
| Revenue Estimate | $521,670 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.28 vs est -0.29 ▲ beat |
| 2026-03-31 | USD -0.24 vs est -0.22 ▼ miss |
| 2025-12-31 | USD -0.18 vs est -0.21 ▲ beat |
| 2025-09-30 | USD -0.29 vs est -0.31 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financials & Fundamentals (PLSE)
| Total Revenue | $1.19M |
|---|---|
| Gross Margin | +0.25% |
| Operating Margin | -5823.04% |
| Profit Margin | +0.00% |
| ROE | -78.49% |
| Debt / Equity | 0.07 |
| Current Ratio | 9.63 |
| Total Cash | $101.62M |
| Total Debt | $6.77M |
| Free Cash Flow (fiscal year ended Dec 2025, SEC 10-K) | -$54.44M (-15553.4% of revenue) |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financial Health Score (PLSE)
Nexqual rates Pulse Biosciences, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:19 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $102M cash vs $7M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$54M (FY ended Dec 2025, 10-K), burning cash |
| Efficiency | Critical — ROE -78%, ROA -44.3% |
Ownership (PLSE)
| Insider Ownership | +71.05% |
|---|---|
| Institutional Ownership | +15.43% |
| Shares Outstanding | 71.32M |
| Float | 20.65M |
| Short % of Float | +15.53% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| WRBY | Warby Parker Inc. | USD 24.59 | ▼ 7.28% |
| ATRC | AtriCure, Inc. | USD 57.78 | ▲ 1.6% |
| NVST | Envista Holdings Corporation | USD 23.5 | ▲ 3.75% |
| ICUI | ICU Medical, Inc. | USD 167.23 | ▲ 2.45% |
| MMED | MiniMed Group, Inc. | USD 18 | ▼ 2.17% |
| STVN | Stevanato Group S.p.A. | USD 19.25 | ▼ 0.05% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:19 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt